» Articles » PMID: 7955775

Enhancement of Drug Absorption by Antacids. An Unrecognised Drug Interaction

Overview
Specialty Pharmacology
Date 1994 Aug 1
PMID 7955775
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Antacids are widely used for many disorders. The potential of antacids to interact with other concomitantly ingested drugs is well recognised. These interactions usually result in reduced or delayed absorption of the affected drug. However, this is not always the case. In contrast to aluminium hydroxide, magnesium hydroxide and sodium bicarbonate can enhance the absorption of some drugs. For example, magnesium hydroxide can increase the rate and sometimes even the extent of absorption of certain nonsteroidal anti-inflammatory drugs (e.g. tolfenamic acid, mefenamic acid and ibuprofen), sulphonylurea antidiabetic agents [e.g. glipizide, glibenclamide (glyburide) and tolbutamide] and the oral anticoagulant dicoumarol (bishydroxycoumarin). These weakly acidic drugs are nonionised at gastric pH, but are sparingly water soluble. Elevation of the gastric pH by administration of magnesium hydroxide or sodium bicarbonate increases the solubility and absorption of such sparingly water soluble agents. Chelate formation may be involved in the increased absorption of dicoumarol by magnesium hydroxide. In combination antacids containing both aluminium hydroxide and magnesium hydroxide, the absorption enhancing effect of magnesium hydroxide seems to be counterbalanced by the opposing effects of aluminium hydroxide. The clinical significance of increased drug absorption is not clear. However, accelerated and enhanced absorption of analgesic drugs may be beneficial when rapid pain relief is desired. In contrast, an unexpectedly increased hypoglycaemic or anticoagulant effect may be potentially dangerous. Therefore, a knowledge of the potential effect of antacids on the absorption of other drugs is clinically important.

Citing Articles

The Impact of Diet and Exercise on Drug Responses.

Niederberger E, Parnham M Int J Mol Sci. 2021; 22(14).

PMID: 34299312 PMC: 8304791. DOI: 10.3390/ijms22147692.


Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs.

Wilton J, Kurenova E, Pitzonka L, Gaudy A, Curtin L, Sexton S Eur J Drug Metab Pharmacokinet. 2014; 41(1):55-67.

PMID: 25377246 PMC: 4424193. DOI: 10.1007/s13318-014-0233-6.


Concomitant prescription of oral fluoroquinolones with an antacid preparation.

Jhaj R, Sivagnanam G J Pharmacol Pharmacother. 2013; 4(2):140-2.

PMID: 23761711 PMC: 3669574. DOI: 10.4103/0976-500X.110898.


Pharmacology of morphine in obese patients: clinical implications.

Lloret Linares C, Decleves X, Oppert J, Basdevant A, Clement K, Bardin C Clin Pharmacokinet. 2009; 48(10):635-51.

PMID: 19743886 DOI: 10.2165/11317150-000000000-00000.


Enteral drug absorption in patients with short small bowel : a review.

Severijnen R, Bayat N, Bakker H, Tolboom J, Bongaerts G Clin Pharmacokinet. 2004; 43(14):951-62.

PMID: 15530127 DOI: 10.2165/00003088-200443140-00001.


References
1.
Weber S, Bankhurst A, Mroszczak E, Ding T . Effect of Mylanta on naproxen bioavailability. Ther Drug Monit. 1981; 3(1):75-83. View

2.
Zuccaro P, Pacifici R, Pichini S, AVICO U, Federzoni G, Pini L . Influence of antacids on the bioavailability of glibenclamide. Drugs Exp Clin Res. 1989; 15(4):165-9. View

3.
Neuvonen P . The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. Br J Clin Pharmacol. 1991; 31(3):263-6. PMC: 1368350. DOI: 10.1111/j.1365-2125.1991.tb05527.x. View

4.
Neuvonen P, Kivisto K . Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol. 1988; 35(5):495-501. DOI: 10.1007/BF00558244. View

5.
Gugler R, Allgayer H . Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet. 1990; 18(3):210-9. DOI: 10.2165/00003088-199018030-00003. View